Nanobiotix/$NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Primary listing
Employees
103
Headquarters
Website
Nanobiotix Metrics
BasicAdvanced
$1.2B
-
-$1.27
1.64
-
Price and volume
Market cap
$1.2B
Beta
1.64
52-week high
$30.35
52-week low
$2.76
Average daily volume
116K
Financial strength
Current ratio
0.633
Quick ratio
0.582
Long term debt to equity
-67.445
Total debt to equity
-74.313
Interest coverage (TTM)
-5.19%
Profitability
EBITDA (TTM)
-51.016
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-508.35%
Operating margin (TTM)
-432.39%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$116,350
Management effectiveness
Return on assets (TTM)
-41.64%
Return on equity (TTM)
113.84%
Valuation
Price to revenue (TTM)
98.349
Price to book
-15.31
Price to tangible book (TTM)
-15.31
Price to free cash flow (TTM)
-31.577
Free cash flow yield (TTM)
-3.17%
Free cash flow per share (TTM)
-0.777
Growth
Revenue change (TTM)
-75.93%
Earnings per share change (TTM)
39.60%
3-year revenue growth (CAGR)
56.37%
10-year revenue growth (CAGR)
11.46%
3-year earnings per share growth (CAGR)
-4.05%
10-year earnings per share growth (CAGR)
1.76%
What the Analysts think about Nanobiotix
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Bulls say / Bears say
An amendment to Nanobiotix’s global licensing agreement with Janssen Pharmaceutica NV in March 2025 shifts nearly all remaining Phase 3 trial costs to J&J, extending its cash runway into mid-2026 and significantly reducing R&D burn (Nasdaq)
The company dosed the first patient in its JNJ-1900 (NBTXR3) CONVERGE Phase 2 trial for Stage 3 unresectable non-small cell lung cancer in January 2025, demonstrating progress in expanding its clinical pipeline in collaboration with J&J (BioSpace)
Early Phase 1 data presented in March 2025 for NSCLC re-irradiation showed favorable safety, injection feasibility, and encouraging efficacy signals with 12-month LPFS of 64% and OS of 83%, underpinning NBTXR3’s therapeutic potential (BioSpace)
Despite extending cash visibility to mid-2026, Nanobiotix’s €28.8 million cash balance as of June 30, 2025 is forecast to be insufficient to fund operations beyond the next twelve months, creating material uncertainty around its going concern status (SEC)
Nanobiotix remains heavily reliant on its amended partnership with Johnson & Johnson and potential non-dilutive financing to sustain development of NBTXR3, exposing the company to significant funding risk if external support diminishes (BioSpace)
NBTXR3 has yet to secure regulatory approval beyond a European CE mark in soft tissue sarcoma, and its commercial viability hinges on successful Phase 3 outcomes and FDA/EMA clearances, which carry inherent trial and approval risks (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Nanobiotix Financial Performance
Revenues and expenses
Nanobiotix Earnings Performance
Company profitability
Nanobiotix News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $1.2B as of October 21, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of October 21, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.